Journal Article
Ups and downs in the experimental treatment of murine typhoid fever using gentamicin combined with caffeine
Esther de Souza Silva; Roseane Thays dos Santos Rocha; Joyce Nayara Gomes da Silva; Victor Vinicius Pereira Ribeiro; Islana Silva Ponte; Isabela Cristina Bandeira Fraga; Camila Sant Ana de Oliveira; Viviane Moreira Lima Galvão; Alison Hideo Jolo Silva; Valdemiro Amaro da Silva Junior; José Vitor Lima-Filho
Brazilian Journal of Microbiology · Vol. 57, Issue 1 · 2026
Abstract
This study assessed whether combining the aminoglycoside gentamicin with caffeine enhances antimicrobial efficacy in a murine typhoid model. We infected murine peritoneal macrophages in vitro with Salmonella enterica serovar Typhimurium and treated them for 24 h with non-toxic concentrations of caffeine (0.05–5 µg/ml) plus gentamicin (10 µg/ml). Subsequently, Swiss mice were orally challenged with S. Typhimurium and received daily intraperitoneal doses of caffeine (0.05-5 mg/kg) plus gentamicin (10 mg/kg) for five days post-infection. Macrophages treated with 5 µg/ml caffeine plus 10 µg/ml gentamicin exhibited significantly higher viability and a marked reduction in intracellular bacterial load. Lower caffeine doses (0.05 and 0.5 µg/ml) failed to preserve cell viability due to uncontrolled bacterial proliferation. Mice receiving gentamicin – either alone or combined with 5 mg/kg caffeine – showed reduced hepatic bacterial burdens and milder histopathological damage. Notably, only the higher caffeine dose enhanced gentamicin’s efficacy; lower caffeine concentrations antagonized the antibiotic’s activity.
Bibliographic Information
| Journal | Brazilian Journal of Microbiology |
|---|
| Publisher | Springer |
|---|
| Publication Date | 2026-12-01 |
|---|
| Publication Year | 2026 |
|---|
| Volume | 57 |
|---|
| Issue | 1 |
|---|
| Document Type | Journal Article |
|---|
| Print ISSN | 1517-8382 |
|---|
| eISSN | 1678-4405 |
|---|
| DOI | 10.1007/s42770-026-01948-2 |
|---|
Access Information
Full-text access depends on NARA's subscribed coverage and institutional access.